Key points:
• The Trump administration has granted Fast Track designation to ARCT-2304, a self-amplifying mRNA vaccine for H5N1 avian influenza.
• BARDA, a key player in Operation Warp Speed, is funding and accelerating the development of this next-generation vaccine technology.
• The vaccine, developed by Arcturus Therapeutics, uses self-replicating mRNA that amplifies immune response within the body's cells.
• The FDA's Fast Track designation aims to expedite the review process, raising concerns about the rapid deployment of experimental technologies.
• The Gates Foundation has committed $782,543 to support the project, further entrenching the public-private partnership model.
• This fast track explains why Gates and Trump met and had a good three hour meeting after Trump was elected in 2024.
A history of hasty vaccine development
Operation Warp Speed, the Trump administration's flagship initiative during the early stages of the COVID-19 scandal, was lauded for its speed but criticized for its lack of transparency and the potential risks it posed to public health. The rapid development and emergency authorization of mRNA vaccines from Pfizer-BioNTech and Moderna, while credited with saving lives, also caused significant side effects and the long-term impacts of these novel technologies. The ARCT-2304 vaccine, which uses self-replicating mRNA, is the latest in a series of fast-tracked projects that continue to push the boundaries of what is considered safe and ethical in vaccine development.
The dangers of self-amplifying mRNA technology
Self-amplifying mRNA vaccines, like ARCT-2304, are designed to replicate within the body's cells, potentially triggering a stronger immune response at lower doses. While this may sound promising, the technology remains largely experimental, and the long-term effects are not yet fully understood. The rapid replication of mRNA within cells could lead to unintended consequences, such as overstimulation of the immune system, which might result in severe adverse reactions. Moreover, the use of self-replicating RNA raises concerns about genetic modification and the potential for unintended genetic changes in the host.
The role of BARDA and the Gates Foundation
BARDA's involvement in the ARCT-2304 project is particularly troubling, given its history with Operation Warp Speed. The agency's expansive authority to fund, coordinate, and fast-track pandemic-related therapeutics and vaccines has been criticized for prioritizing speed over safety. The Gates Foundation's commitment of $782,543 to support the project further entrenches the public-private partnership model, which has been a source of controversy due to the potential for conflicts of interest and lack of accountability.
The Trump administration's continued support for these experimental technologies, despite the known risks and failures of Operation Warp Speed, is deeply concerning. The Fast Track designation for ARCT-2304 is a clear indication that the administration is more interested in rapid deployment than in ensuring the safety and efficacy of these vaccines. This approach not only puts public health at risk but also undermines trust in the regulatory process.
The recent dinner between Bill Gates and President Trump at Mar-a-Lago, where they discussed global health initiatives, further highlights the administration's alignment with private interests. Gates, a long-time advocate for vaccine technologies, has a vested interest in the success of these projects, and his influence on the administration's health policies is evident. The conversation, which lasted about three hours, reportedly focused on the importance of maintaining programs like the President's Emergency Plan for AIDS Relief (PEPFAR) and the potential for accelerated medical innovation. However, this alignment with private interests raises questions about the true motivations behind the administration's vaccine agenda.
Sources include:
Please contact us for more information.